Furosemide 50mg/5ml solution for injection ampoules

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Furosemide

Pieejams no:

hameln pharma Ltd

ATĶ kods:

C03CA01

SNN (starptautisko nepatentēto nosaukumu):

Furosemide

Deva:

10mg/1ml

Zāļu forma:

Solution for injection

Ievadīšanas:

Intravenous; Intramuscular

Klase:

No Controlled Drug Status

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 02020200; GTIN: 5016386000324

Lietošanas instrukcija

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FUROSEMIDE INJECTION
Furosemide
•
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU
.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
What is in this leaflet
1. What Furosemide Injection is and what it is used for
2. What you need to know before Furosemide Injection is given to you
3. How Furosemide Injection is given to you
4. Possible side effects
5. How to store Furosemide Injection
6. Contents of the pack and other information
HAMELN
1. What Furosemide Injection is and what it
is used for
Furosemide Injection is a powerful, quick acting
diuretic which causes the body to increase the
production of urine. It is used to:
• remove
large
amounts
of
fluid
that
has
accumulated in the tissues and lungs (oedema)
• treat high blood pressure in emergencies
• increase the production of urine in kidney failure.
2. What you need to know before Furosemide
Injection is given to you
YOU SHOULD NOT BE GIVEN FUROSEMIDE
INJECTION IF:
• You are allergic to Furosemide Injection or any
of the other ingredients of this medicine (listed in
section 6). If you are allergic to a group of drugs
called
sulfonamides
(e.g.
Co-Trimoxazole,
sulfadiazine)
or
sulfonamide
derivatives
and
amiloride
you
may
also
be
allergic
to
this
injection.
• You are dehydrated, your blood volume is low
(you may feel dizzy, faint or have pale skin) or
you are unable to pass urine.
• You have low levels of potassium or sodium or
an imbalance of chemicals in your blood (shown
in a blood test).
• You have severe liver problems (cirrhosis) that
are affecting your consciousness.
• You previously received certain medicines that
have damaged your kidneys or liver.
• You have already taken furosemide in the past
to treat f

Produkta apraksts

OBJECT 1
FUROSEMIDE INJECTION BP (HAMELN)
Summary of Product Characteristics Updated 12-May-2017 | hameln
pharmaceuticals ltd
1. Name of the medicinal product
Furosemide Injection BP.
2. Qualitative and quantitative composition
Each ml contains 10mg of Furosemide BP.
For a full list of excipients, see Section 6.1
3. Pharmaceutical form
Sterile injection.
4. Clinical particulars
4.1 Therapeutic indications
Furosemide is a potent diuretic with a rapid action.
It is used to treat oedema and hypertensive crises; acute or chronic
renal failure.
4.2 Posology and method of administration
Posology
_Adults_
Doses of 20 to 50 mg intramuscularly or intravenously may be given
initially. If larger doses are required,
they should be given increasing by 20 mg increments and not given more
often than every two hours. If
doses greater than 50 mg are required it is recommended that they be
given by slow intravenous infusion.
The recommended maximum daily dose of furosemide administration is
1,500 mg.
_Elderly_
The dosage recommendations for adults apply, but in the elderly
furosemide is generally eliminated more
slowly. Dosage should be titrated until the required response is
achieved.
_Paediatric population_
Parenteral doses for children range from 0.5 to 1.5 mg/kg body weight
daily up to a maximum total daily
dose of 20 mg.
Method of administration
Furosemide is administered intravenously or intramuscularly.
Intravenous furosemide must be injected or infused slowly; a rate of 4
mg per minute must not be
exceeded. In patients with severe impairment of renal function (serum
creatinine>5 mg/dl), it is
recommended that an infusion rate of 2.5 mg per minute is not
exceeded.
Intramuscular administration must be restricted to exceptional cases
where neither oral nor intravenous
administration are feasible. It must be noted that intramuscular
injection is not suitable for the treatment
of acute conditions such as pulmonary oedema.
To achieve optimum efficacy and suppress counter-regulation, a
continuous furosemide infusion is
generally